NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of Several Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Used Indinavir

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 300

Registration Number: NCT00000892

Locations: 🇺🇸
Cornell Univ Med Ctr, New York, New York, United States
🇺🇸
Mount Sinai Med Ctr, New York, New York, United States
🇺🇸
Univ of Tennessee / E Tennessee Comprehensive Hemophilia Ctr, Knoxville, Tennessee, United States

and more 42 locations

A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 30

Registration Number: NCT00000757

Locations: 🇺🇸
St. Louis Univ. School of Medicine AVEG, Saint Louis, Missouri, United States

A Phase I Trial of Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (rHuGM-CSF), Recombinant Alpha Interferon and Azidothymidine (AZT) in AIDS-Associated Kaposi's Sarcoma

Phase 1

Completed

Conditions: HIV Infections
Sarcoma, Kaposi

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 18

Registration Number: NCT00000694

Locations: 🇺🇸
Mem Sloan - Kettering Cancer Ctr, New York, New York, United States

Safety and Effectiveness of a Three-Drug Combination Treatment for Recently Infected or Converted HIV Patients

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 55

Registration Number: NCT00007202

Locations: 🇺🇸
AIDS Research Consortium of Atlanta, Inc. (ARCA) AIEDRP CRS, Atlanta, Georgia, United States
🇺🇸
Feinberg School of Medicine, HIV/ACTU AIEDRP CRS, Chicago, Illinois, United States
🇺🇸
Rush Univ. Med. Ctr., Dept. of Infectious Disease AIEDRP CRS, Chicago, Illinois, United States

and more 2 locations

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of Low Dose MN rsgp120/HIV-1 (Genentech) in Combination With QS21 Adjuvant or Alum in Healthy Adults

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 37

Registration Number: NCT00000853

Locations: 🇺🇸
UAB AVEG, Birmingham, Alabama, United States
🇺🇸
Univ. of Rochester AVEG, Rochester, New York, United States
🇺🇸
UW - Seattle AVEG, Seattle, Washington, United States

The Safety and Effectiveness of Human Monoclonal Antibody, F105, in the Treatment of HIV

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 8

Registration Number: NCT00001105

Locations: 🇺🇸
Beth Israel Deaconess Med. Ctr., ACTG CRS, Boston, Massachusetts, United States

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 112

Registration Number: NCT00001042

Locations: 🇺🇸
St. Louis Univ. School of Medicine AVEG, Saint Louis, Missouri, United States
🇺🇸
Univ. of Rochester AVEG, Rochester, New York, United States
🇺🇸
UW - Seattle AVEG, Seattle, Washington, United States

A Study of Itraconazole in Preventing the Return of Histoplasmosis, a Fungal Infection, in Patients With AIDS

Phase 1

Completed

Conditions: HIV Infections
Histoplasmosis

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 30

Registration Number: NCT00000992

Locations: 🇺🇸
Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis, Indiana, United States
🇺🇸
Univ. of Cincinnati CRS, Cincinnati, Ohio, United States
🇺🇸
Washington U CRS, Saint Louis, Missouri, United States

and more 5 locations

Study of a New Anti-HIV Drug, T-20, in HIV-Infected Children

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 24

Registration Number: NCT00001118

Locations: 🇺🇸
Long Beach Memorial (Pediatric), Long Beach, California, United States
🇺🇸
Univ of Florida Health Science Ctr / Pediatrics, Jacksonville, Florida, United States
🇺🇸
Harlem Hosp Ctr, New York, New York, United States

and more 22 locations

The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 300

Registration Number: NCT00001087

Locations: 🇺🇸
Rush Univ. Med. Ctr. ACTG CRS, Chicago, Illinois, United States
🇺🇸
Cook County Hosp. CORE Ctr., Chicago, Illinois, United States
🇺🇸
Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy